203 related articles for article (PubMed ID: 27217417)
1. Calprotectin is a potential prognostic marker for polycystic ovary syndrome.
Chen S; Jiang M; Ding T; Wang J; Long P
Ann Clin Biochem; 2017 Mar; 54(2):253-257. PubMed ID: 27217417
[TBL] [Abstract][Full Text] [Related]
2. Elevated serum levels of anti-Müllerian hormone can be introduced as a new diagnostic marker for polycystic ovary syndrome.
Sahmay S; Atakul N; Aydogan B; Aydin Y; Imamoglu M; Seyisoglu H
Acta Obstet Gynecol Scand; 2013 Dec; 92(12):1369-74. PubMed ID: 23980726
[TBL] [Abstract][Full Text] [Related]
3. Serum betatrophin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome.
Qu Q; Zhao D; Zhang F; Bao H; Yang Q
J Int Med Res; 2017 Feb; 45(1):193-202. PubMed ID: 28222635
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary study on the value of ratio of serum luteinizing hormone/follicle-stimulating hormone in diagnosis of polycystic ovarian syndrome among women with polycystic ovary].
Ma CS; Lin Y; Zhang CH; Xu H; Li YF; Zhang SC; Tan Y; Quan S; Xing FQ
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):177-80. PubMed ID: 21575449
[TBL] [Abstract][Full Text] [Related]
5. The correlation of plasma omentin-1 with insulin resistance in non-obese polycystic ovary syndrome.
Yang HY; Ma Y; Lu XH; Liang XH; Suo YJ; Huang ZX; Lu DC; Qin YF; Luo ZJ
Ann Endocrinol (Paris); 2015 Oct; 76(5):620-7. PubMed ID: 26514948
[TBL] [Abstract][Full Text] [Related]
6. Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.
Yilmaz SA; Kerimoglu OS; Pekin AT; Incesu F; Dogan NU; Celik C; Unlu A
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():56-60. PubMed ID: 25020276
[TBL] [Abstract][Full Text] [Related]
7. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome.
Yucel A; Noyan V; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):81-6. PubMed ID: 16337726
[TBL] [Abstract][Full Text] [Related]
8. [Insulin resistance and serum concentrations of ovarian and adrenal androgen in obese women without additional disease and with policystic ovary syndrome].
Olszanecka-Glinianowicz M; Banaś M; Zahorska-Markiewicz B; Kuglin D; Mokrzycka J; Mentel A
Endokrynol Pol; 2005; 56(6):921-6. PubMed ID: 16821212
[TBL] [Abstract][Full Text] [Related]
9. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.
Pigny P; Jonard S; Robert Y; Dewailly D
J Clin Endocrinol Metab; 2006 Mar; 91(3):941-5. PubMed ID: 16368745
[TBL] [Abstract][Full Text] [Related]
10. Serum HLA-G levels in women with polycystic ovary syndrome.
Oztekin O; Fenkci SM; Fenkci V; Enli Y; Cabus U
Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
[TBL] [Abstract][Full Text] [Related]
11. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
12. Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.
La Marca A; Orvieto R; Giulini S; Jasonni VM; Volpe A; De Leo V
Fertil Steril; 2004 Oct; 82(4):970-2. PubMed ID: 15482785
[TBL] [Abstract][Full Text] [Related]
13. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
Sir-Petermann T; Ladrón de Guevara A; Codner E; Preisler J; Crisosto N; Echiburú B; Maliqueo M; Sánchez F; Perez-Bravo F; Cassorla F
Reprod Sci; 2012 Apr; 19(4):383-90. PubMed ID: 22344736
[TBL] [Abstract][Full Text] [Related]
14. Serum anti-Müllerian hormone and polycystic ovary syndrome: a matter of methods?
Parco S; Novelli C; Princi T
Minerva Pediatr; 2014 Aug; 66(4):335-6. PubMed ID: 25198571
[No Abstract] [Full Text] [Related]
15. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1995 Oct; 80(10):2966-73. PubMed ID: 7559882
[TBL] [Abstract][Full Text] [Related]
16. Macrophage migration inhibitory factor in obese and non obese women with polycystic ovary syndrome.
Mejia-Montilla J; Álvarez-Mon M; Reyna-Villasmil E; Torres-Cepeda D; Santos-Bolívar J; Reyna-Villasmil N; Suarez-Torres I; Bravo-Henríquez A
Endocrinol Nutr; 2015 Jan; 62(1):31-7. PubMed ID: 25458401
[TBL] [Abstract][Full Text] [Related]
17. The impact of insulin resistance on the outcome of laparoscopic ovarian diathermy in women with polycystic ovarian syndrome.
Amer S; Li TC; Samuelson C; Ledger W
Acta Obstet Gynecol Scand; 2011 Apr; 90(4):338-43. PubMed ID: 21306324
[TBL] [Abstract][Full Text] [Related]
18. Serum calprotectin--a promising diagnostic marker for adult-onset Still's disease.
Guo Q; Zha X; Li C; Jia Y; Zhu L; Guo J; Su Y
Clin Rheumatol; 2016 Jan; 35(1):73-9. PubMed ID: 26547221
[TBL] [Abstract][Full Text] [Related]
19. The effect of weight loss on inflammation in obese women with polycystic ovary syndrome.
Olszanecka-Glinianowicz M; Zahorska-Markiewicz B; Kocełak P; Janowska J; Semik-Grabarczyk E
Endokrynol Pol; 2008; 59(1):13-7. PubMed ID: 18335395
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus.
Kelestimur F; Unluhizarci K; Baybuga H; Atmaca H; Bayram F; Sahin Y
Fertil Steril; 2006 Aug; 86(2):405-10. PubMed ID: 16762349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
